BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ampyra / Fampyra (Fampridine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ampyra / Fampyra (Fampridine)\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06751784-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2 readout est. (NCT06751784)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2.\nStudy: Cross-over Stu
 dy on the Influence of Fampridine on Working Memory in Mild to Moderate De
 pression\nEstimated primary completion: 31 March 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06751784
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136728-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 3 readout est. (NCT06136728)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 3\, Multiple Sclerosis.\n
 Study: Dalfampridine Combined With Physical Therapy for Mobility Impairmen
 t in Multiple Sclerosis\nEstimated primary completion: May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06136728
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185347-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 3 readout est. (NCT07185347)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 3.\nStudy: A Randomized\,
  Parallel-arm\, Double Blind\, Placebo-controlled Study to Assess the Effi
 cacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused 
 by a GAA Expansion in the FGF14 Gene\nEstimated primary completion: 21 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0718534
 7
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03701581-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2/3 readout est. (NCT03701581)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2/3.\nStudy: 4-aminopyrid
 ine Treatment for Nerve Injury\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03701581
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07922122-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:Ampyra / Fampyra (Fampridine): Phase na readout est. (NCT07922122)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase na.\nStudy: Transcutaneou
 s Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Reha
 bilitation in SCI\nEstimated primary completion: 8 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07922122
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532460-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ampyra / Fampyra (Fampridine): Phase na readout est. (NCT07532460)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase na.\nStudy: The Role of P
 otassium Channels in Working Memory Impairments of Chronic Cocaine Users\n
 Estimated primary completion: August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fampridine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07532460
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06333171-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2 readout est. (NCT06333171)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2.\nStudy: 4-aminopyridin
 e for Skin Wound Healing\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06333171
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06294821-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2 readout est. (NCT06294821)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2.\nStudy: 4AP for Carpal
  Tunnel Syndrome (CTS)\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06294821
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832331-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 1 readout est. (NCT07832331)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 1.\nStudy: Single Dose 4-
 Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis Continuit
 y After Trauma\nEstimated primary completion: 1 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07832331
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06003166-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2 readout est. (NCT06003166)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2.\nStudy: 4-AP Periphera
 l Nerve Crossover Trial\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06003166
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06596434-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 2 readout est. (NCT06596434)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 2.\nStudy: 4-Aminopyridin
 e to Treat Skin Burns\nEstimated primary completion: June 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06596434
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07171203-7078@assetmemo.bio
DTSTAMP:20261121T004036Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 1 readout est. (NCT07171203)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 1.\nStudy: Preoperative I
 matinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor\nEstim
 ated primary completion: July 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/fampridine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07171203
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
